Cargando…
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER progr...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605190/ https://www.ncbi.nlm.nih.gov/pubmed/34794033 http://dx.doi.org/10.1016/j.tranon.2021.101266 |
_version_ | 1784602123777867776 |
---|---|
author | Cassier, Philippe A. Peyramaure, Clémentine Attignon, Valery Eberst, Lauriane Pacaud, Camille Boyault, Sandrine Desseigne, Françoise Sarabi, Mathieu Guibert, Pierre Rochefort, Pauline Marques, Nathalie Rivoire, Michel Dupré, Aurélien Peyrat, Patrice Terret, Catherine Ray-Coquard, Isabelle Coutzac, Clélia Pérol, David Blay, Jean-Yves Trédan, Olivier de la Fouchardière, Christelle |
author_facet | Cassier, Philippe A. Peyramaure, Clémentine Attignon, Valery Eberst, Lauriane Pacaud, Camille Boyault, Sandrine Desseigne, Françoise Sarabi, Mathieu Guibert, Pierre Rochefort, Pauline Marques, Nathalie Rivoire, Michel Dupré, Aurélien Peyrat, Patrice Terret, Catherine Ray-Coquard, Isabelle Coutzac, Clélia Pérol, David Blay, Jean-Yves Trédan, Olivier de la Fouchardière, Christelle |
author_sort | Cassier, Philippe A. |
collection | PubMed |
description | BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER program. RESULTS: Adenocarcinoma (n = 86, 59%), signet-cell (n = 37, 25%) and squamous-cell (n = 21, 14%) were the dominant histology amongst 147 patients. Genomic analyses could be performed for 114 (78%) patients. The most common genomic alterations involved ERBB2 (15%), KRAS (12%), CCND1 (7%), FGFR1–3 (8%), EGFR (5%) and MET (3%), TP53 (51%) and CDKN2A/B (10%). ERBB2, MET and FGFR alterations were found exclusively in the adenocarcinoma and signet-cell subtypes, while CCND1 amplification, TP53 mutations and CDKN2A/B loss were found in both adenocarcinoma and squamous-cell subtypes. Nine patients (8%) received therapy matched to their genomic alteration, with 5 of them achieving disease control. In an exploratory analysis, patients with stage IV disease at diagnosis who had an actionable alteration had longer overall survival compared to those without. CONCLUSION: Genomic profiling for patients with advanced gastroesophageal cancers allows the identification of actionable alterations in large proportion of patients. Increased accessibility to molecularly matched therapy may improve survival in this disease. |
format | Online Article Text |
id | pubmed-8605190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86051902021-11-26 Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program Cassier, Philippe A. Peyramaure, Clémentine Attignon, Valery Eberst, Lauriane Pacaud, Camille Boyault, Sandrine Desseigne, Françoise Sarabi, Mathieu Guibert, Pierre Rochefort, Pauline Marques, Nathalie Rivoire, Michel Dupré, Aurélien Peyrat, Patrice Terret, Catherine Ray-Coquard, Isabelle Coutzac, Clélia Pérol, David Blay, Jean-Yves Trédan, Olivier de la Fouchardière, Christelle Transl Oncol Original Research BACKGROUND: Chemotherapy, anti-HER2 and PD-1 antibodies are standard treatments but only a minority of patients derive long-term benefit from these agents. METHODS: In this report we describe the mutational landscape and outcome of patients with gastroesophageal cancers enroled in the ProfiLER program. RESULTS: Adenocarcinoma (n = 86, 59%), signet-cell (n = 37, 25%) and squamous-cell (n = 21, 14%) were the dominant histology amongst 147 patients. Genomic analyses could be performed for 114 (78%) patients. The most common genomic alterations involved ERBB2 (15%), KRAS (12%), CCND1 (7%), FGFR1–3 (8%), EGFR (5%) and MET (3%), TP53 (51%) and CDKN2A/B (10%). ERBB2, MET and FGFR alterations were found exclusively in the adenocarcinoma and signet-cell subtypes, while CCND1 amplification, TP53 mutations and CDKN2A/B loss were found in both adenocarcinoma and squamous-cell subtypes. Nine patients (8%) received therapy matched to their genomic alteration, with 5 of them achieving disease control. In an exploratory analysis, patients with stage IV disease at diagnosis who had an actionable alteration had longer overall survival compared to those without. CONCLUSION: Genomic profiling for patients with advanced gastroesophageal cancers allows the identification of actionable alterations in large proportion of patients. Increased accessibility to molecularly matched therapy may improve survival in this disease. Neoplasia Press 2021-11-15 /pmc/articles/PMC8605190/ /pubmed/34794033 http://dx.doi.org/10.1016/j.tranon.2021.101266 Text en © 2021 Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Research Cassier, Philippe A. Peyramaure, Clémentine Attignon, Valery Eberst, Lauriane Pacaud, Camille Boyault, Sandrine Desseigne, Françoise Sarabi, Mathieu Guibert, Pierre Rochefort, Pauline Marques, Nathalie Rivoire, Michel Dupré, Aurélien Peyrat, Patrice Terret, Catherine Ray-Coquard, Isabelle Coutzac, Clélia Pérol, David Blay, Jean-Yves Trédan, Olivier de la Fouchardière, Christelle Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program |
title | Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program |
title_full | Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program |
title_fullStr | Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program |
title_full_unstemmed | Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program |
title_short | Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program |
title_sort | precision medicine for patients with gastro-oesophageal cancer: a subset analysis of the profiler program |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605190/ https://www.ncbi.nlm.nih.gov/pubmed/34794033 http://dx.doi.org/10.1016/j.tranon.2021.101266 |
work_keys_str_mv | AT cassierphilippea precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT peyramaureclementine precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT attignonvalery precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT eberstlauriane precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT pacaudcamille precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT boyaultsandrine precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT desseignefrancoise precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT sarabimathieu precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT guibertpierre precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT rochefortpauline precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT marquesnathalie precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT rivoiremichel precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT dupreaurelien precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT peyratpatrice precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT terretcatherine precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT raycoquardisabelle precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT coutzacclelia precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT peroldavid precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT blayjeanyves precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT tredanolivier precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram AT delafouchardierechristelle precisionmedicineforpatientswithgastrooesophagealcancerasubsetanalysisoftheprofilerprogram |